We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.
Citations
Citations to this article as recorded by
Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui Infection.2023; 51(1): 213. CrossRef
Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite Loick P. Kojom Foko, Amit Kumar, Joseph Hawadak, Vineeta Singh Infection.2023; 51(3): 623. CrossRef
The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients Ziyu Zhang, Qinhui Li, Xiaoyan Shen, Lankai Liao, Xia Wang, Min Song, Xi Zheng, Yulian Zhu, Yong Yang Frontiers in Pharmacology.2022;[Epub] CrossRef
G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs Germana Bancone, Cindy S. Chu Frontiers in Pharmacology.2021;[Epub] CrossRef
Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps Jyotsna Chawla, Jenna Oberstaller, John H. Adams Pathogens.2021; 10(3): 346. CrossRef
Recent Advances in Transmission-Blocking Drugs for Malaria Elimination Ishan Wadi, Mahendra Nath, Anupkumar R Anvikar, Pargat Singh, Abhinav Sinha Future Medicinal Chemistry.2019; 11(23): 3047. CrossRef
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients Sara Avalos, Rosa E. Mejia, Engels Banegas, Cesar Salinas, Lester Gutierrez, Marcela Fajardo, Suzeth Galo, Alejandra Pinto, Angel Mejia, Gustavo Fontecha Malaria Journal.2018;[Epub] CrossRef
A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications Hazem Elewa, Kyle John Wilby European Journal of Drug Metabolism and Pharmacokinetics.2017; 42(5): 745. CrossRef
Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies Olalekan A. Uthman, Patricia M. Graves, Rachel Saunders, Hellen Gelband, Marty Richardson, Paul Garner Malaria Journal.2017;[Epub] CrossRef
Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba BMJ Global Health.2017; 2(3): e000415. CrossRef
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana Annals of the Academy of Medicine, Singapore.2016; 45(7): 303. CrossRef
Enantioselective Pharmacokinetics of Primaquine in Healthy Human Volunteers Babu L Tekwani, Bharathi Avula, Rajnish Sahu, Narayan D Chaurasiya, Shabana I Khan, Surendra Jain, Pius S Fasinu, H.M.T. Bandara Herath, Donald Stanford, N.P. Dhammika Nanayakkara, James D McChesney, Travis W Yates, Mahmoud A ElSohly, Ikhlas A Khan, Larry Drug Metabolism and Disposition.2015; 43(4): 571. CrossRef
“Recycling” Classical Drugs for Malaria Cátia Teixeira, Nuno Vale, Bianca Pérez, Ana Gomes, José R. B. Gomes, Paula Gomes Chemical Reviews.2014; 114(22): 11164. CrossRef
KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro Anne-Marie Zeeman, Sandra M. van Amsterdam, Case W. McNamara, Annemarie Voorberg-van der Wel, Els J. Klooster, Alexander van den Berg, Edmond J. Remarque, David M. Plouffe, Geert-Jan van Gemert, Adrian Luty, Robert Sauerwein, Kerstin Gagaring, Rachel Borb Antimicrobial Agents and Chemotherapy.2014; 58(3): 1586. CrossRef
Novel approaches in antimalarial drug discovery Jana Held, Andrea Kreidenweiss, Benjamin Mordmüller Expert Opinion on Drug Discovery.2013; 8(11): 1325. CrossRef
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef
Effects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate Odile Dechy-Cabaret, Françoise Benoit-Vical Journal of Medicinal Chemistry.2012; 55(23): 10328. CrossRef
Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal Tiago Rodrigues, Miguel Prudêncio, Rui Moreira, Maria M. Mota, Francisca Lopes Journal of Medicinal Chemistry.2012; 55(3): 995. CrossRef
PharmGKB summary Ellen M. McDonagh, Caroline F. Thorn, José M. Bautista, Ilan Youngster, Russ B. Altman, Teri E. Klein Pharmacogenetics and Genomics.2012; 22(3): 219. CrossRef
New approaches in antimalarial drug discovery and development: a review Anna Caroline C Aguiar, Eliana MM da Rocha, Nicolli B de Souza, Tanos CC França, Antoniana U Krettli Memórias do Instituto Oswaldo Cruz.2012; 107(7): 831. CrossRef
Plasmodium vivax treatments Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein Current Opinion in Infectious Diseases.2011; 24(6): 578. CrossRef
Feeding the Antimalarial Pipeline Martin Schlitzer, Regina Ortmann ChemMedChem.2010; 5(11): 1837. CrossRef
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird Trends in Parasitology.2010; 26(3): 145. CrossRef
Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials Anthony E. Kiszewski Pharmaceuticals.2010; 4(1): 44. CrossRef
Medications and Glucose-6-Phosphate Dehydrogenase Deficiency Ilan Youngster, Lidia Arcavi, Renata Schechmaster, Yulia Akayzen, Hen Popliski, Janna Shimonov, Svetlana Beig, Matitiahu Berkovitch Drug Safety.2010; 33(9): 713. CrossRef
A pre-emptive strike against malaria's stealthy hepatic forms Dominique Mazier, Laurent Rénia, Georges Snounou Nature Reviews Drug Discovery.2009; 8(11): 854. CrossRef
Resistance to Therapies for Infection byPlasmodium vivax J. Kevin Baird Clinical Microbiology Reviews.2009; 22(3): 508. CrossRef
8-Aminoquinolines: future role as antiprotozoal drugs Babu L Tekwani, Larry A Walker Current Opinion in Infectious Diseases.2006; 19(6): 623. CrossRef
First
Prev
